Forma Therapeautics targets essential cancer pathways to create transformative medicines.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/13/12 | $10,000,000 | Seed | ||
| 12/19/19 | $100,000,000 | Series D |
Cormorant Asset Management Janus Henderson Investors RA Capital Management  Samsara BioCapital Wellington Capital Management | undisclosed |
